-
Morgan Stanley Upgrades Gilead Sciences, Says It Will Maintain 75% Market Share
Monday, December 29, 2014 - 4:08pm | 145Read More...Morgan Stanley upgraded Gilead Sciences, Inc. (NASDAQ: GILD) from Equal-weight to Overweight on Monday and raised its price target from $100 to $104. Analyst Matthew Harrison felt that price fears were exaggerated. Analysts at Bank of America and Deutsche Bank predicted a possible price war...
-
Jefferies Maintains Rating, PT On ESRX In Advance Of 1Q11 Results
Tuesday, April 26, 2011 - 8:51am | 105Read More...Jefferies is maintaining its Buy rating and price target of $69 on Express Scripts (NASDAQ: ESRX) as the company prepares to unveil its 1Q11 results. According to Jefferies, “Investors will likely be disappointed with ESRX's below-consensus Q1 earnings and will penalize the stock accordingly....
